EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Effect of Posterior Nasal Nerve Ablation on Biomarker Expression in Patients With Chronic Rhinitis

Elina Toskala, Katie M. Phillips, Bryan Davis, Shannon Lynch, Larry Harshyne

Laryngoscope Investigative Otolaryngology · 2026-12 · 11 (6)

DOI: 10.1002/lio2.70628 ↗

At a glance

Journal article in Laryngoscope Investigative Otolaryngology, published online on 2026-11-18. Written by Elina Toskala and 4 co-authors. 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This study evaluated changes in inflammatory and neurogenic biomarkers in nasal secretions in relation to clinical outcomes following temperature‐controlled radiofrequency ( TCRF) posterior nasal nerve (PNN) ablation in patients with allergic ( AR ) and nonallergic ( NAR ) chronic rhinitis (CR) .

Methods

In this prospective multicenter study, 25 participants with moderate to severe CR underwent TCRF PNN ablation. Nasal secretions were collected at baseline and 3 months postprocedure and analyzed for inflammatory biomarkers ( ECP , EGF , IFNγ , IgE , IL ‐1β, IL ‐4, IL ‐5, IL ‐6, IL ‐8, IL ‐10, IL ‐13, IL ‐ 17A , IL ‐ 17F , IL ‐22, IL ‐25, TNFα ) and TRPV1 , a sensory nerve marker. Reflective total nasal symptom scores ( rTNSS ) were assessed from baseline through 6 months.

Results

Mean rTNSS decreased from 7.8 (95% CI: 7.0 to 8.7) at baseline to 4.3 (95% CI: 3.2 to 5.4) at 3 months, a 46% improvement; 75% of participants met responder criteria. Reductions were observed in TRPV1 (0.76‐fold) and in epithelial derived IL ‐25 (0.89‐fold) across AR and NAR patients. Reductions in IL ‐8 were associated with greater treatment response.

Conclusions

TCRF PNN ablation was associated with symptom improvement in both AR and NAR patients with reduction in neurogenic and epithelial biomarkers, including TRPV1 and IL ‐25. These findings provide preliminary evidence that TCRF PNN ablation may be a neuroimmune modulatory therapy for CR . Level of Evidence 3. Trial Registration ClinicalTrials.gov (NCT06599736)

Cite

APA

Toskala, E., Phillips, K. M., Davis, B., Lynch, S., & Harshyne, L. (2026). Effect of Posterior Nasal Nerve Ablation on Biomarker Expression in Patients With Chronic Rhinitis. Laryngoscope Investigative Otolaryngology, 11(6). https://doi.org/10.1002/lio2.70628

Vancouver

Toskala E, Phillips KM, Davis B, Lynch S, Harshyne L. Effect of Posterior Nasal Nerve Ablation on Biomarker Expression in Patients With Chronic Rhinitis. Laryngoscope Investigative Otolaryngology. 2026;11(6). doi:10.1002/lio2.70628

BibTeX
@article{Toskala2026,
  author = {Toskala, Elina and Phillips, Katie M. and Davis, Bryan and Lynch, Shannon and Harshyne, Larry},
  title = {Effect of Posterior Nasal Nerve Ablation on Biomarker Expression in Patients With Chronic Rhinitis},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {6},
  doi = {10.1002/lio2.70628}
}
Start for free →